Study of Olutasidenib and Temozolomide in HGG
A phase 2 trial of Olutasidenib in diffuse midline glioma, h3 k27-altered, run by Rigel Pharmaceuticals, now recruiting.
Overview
Study of Olutasidenib and Temozolomide in HGG is a phase 2 interventional study registered as NCT06161974 by Rigel Pharmaceuticals, with 60 participants planned, started 2025-02-01 and due to reach its primary completion in 2029-06. Interventions recorded: Olutasidenib + TMZ. Conditions listed: High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV. No results are recorded here; the registry entry is the source.
Setting
Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations
Phase
Phase 2
Sponsor
Rigel Pharmaceuticals
Registry
Enrolled
60